We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Aptinyx

News List

Aptinyx’s NYX-2925 Demonstrates Positive Data in Fibromyalgia contractpharma
June 21, 2019
Phase 2 clinical study showed significant effects on both neuroimaging biomarkers and patient-reported outcomes, including pain scores.
Aptinyx, Magenta lead biotech IPO flurry ahead of summer lull fiercebiotech
June 25, 2018
No fewer than five biotech IPOs debuted Thursday, raising more than $460 million and with more in the offing if underwriters take up further options.
Aptinyx seeks $80M IPO to push NMDA drug platform fiercebiotech
May 29, 2018
With the ink barely dry on a partnership deal with Allergan, Aptinyx has announced plans for an $80 million IPO to accelerate work on its drugs for neurological disorders.
Aptinyx Bags $70M Financing to Fuel Expanding Pipeline biospace
December 20, 2017
Aptinyx closed on a Series B financing worth $70 million.